- Current Antiviral Therapy for Chronic Hepatitis B
-
Lim YS, Suh DJ
- KMID: 2157673
- J Korean Med Sci.
- 2004 Aug;19(4):489-494.
- doi: 10.3346/jkms.2004.19.4.489
During the past decade, major breakthroughs have been achieved in treatment of chronic hepatitis B. Currently, three therapeutic agents are approved for chronic hepatitis B: interferon-alpha, lamivudine and adefovir dipivoxil.... -
- CITED
-
- Close
- SHARE
-
- Close
- Clevudine therapy in patients with chronic hepatitis B
-
Lee KS
- KMID: 1381432
- Korean J Hepatol.
- 2009 Jun;15(2):119-121.
- doi: 10.3350/kjhep.2009.15.2.119
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Chronic Hepatitis B in Treatment-Naive Patients
-
Cheong JY
- KMID: 1767538
- Korean J Gastroenterol.
- 2008 Jun;51(6):338-345.
Chronic hepatitis B (CHB) is a serious health problem in Korea. The natural history of chronic HBV infection has been divided into 4 phases: immune tolerance, immune clearance, inactive HBsAg... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Antiviral-Resistant Chronic Hepatitis B Virus Infection
-
Yim HJ
- KMID: 1767539
- Korean J Gastroenterol.
- 2008 Jun;51(6):346-359.
Substantial progress has been made in the treatment of chronic hepatitis B during the past decade. Nucleos(t)ide analogues are now widely used due to their convenience, less side effects, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Antiviral Resistance in Chronic Hepatitis B
-
Lim YS
- KMID: 2412184
- Gut Liver.
- 2017 Mar;11(2):189-195.
- doi: 10.5009/gnl15562
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of 48-week clevudine therapy for chronic hepatitis B
-
Kim MH, Kim KA, Lee JS, Lee HW, Kim HJ, Yun SG, Kim NH, Bae WK, Moon YS
- KMID: 1374961
- Korean J Hepatol.
- 2009 Sep;15(3):331-337.
- doi: 10.3350/kjhep.2009.15.3.331
BACKGROUND/AIMS: Clevudine is a nucleoside analogue that exhibits potent and sustained antiviral effects as a 24-week therapy for chronic hepatitis B (CHB). This study evaluated the efficacy and viral resistance... -
- CITED
-
- Close
- SHARE
-
- Close
- Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
-
Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS, Byun KS
- KMID: 1792604
- Korean J Hepatol.
- 2011 Dec;17(4):261-267.
- doi: 10.3350/kjhep.2011.17.4.261
BACKGROUND/AIMS: We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Reverse Transcriptase Gene Mutations in the Hepatitis B Virus at a University Hospital in Korea
-
Lee AJ, Lee CH, Jeon CH
- KMID: 1791925
- Ann Lab Med.
- 2014 May;34(3):230-234.
- doi: 10.3343/alm.2014.34.3.230
BACKGROUND: Most mutations in the reverse transcriptase (RT) gene of the hepatitis B virus (HBV) are related to resistance to antiviral agents. Cross-sectional studies on the mutations of this gene... -
- CITED
-
- Close
- SHARE
-
- Close
- Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naive and nucleos(t)ide analogue-experienced chronic hepatitis B patients
-
Jung SK, Kim KA, Ha SY, Lee HK, Kim YD, Lee BH, Paik WH, Kim JW, Bae WK, Kim NH, Lee JS, Jwa YJ
- KMID: 2155290
- Clin Mol Hepatol.
- 2015 Mar;21(1):41-48.
- doi: 10.3350/cmh.2015.21.1.41
BACKGROUND/AIMS: This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients. METHODS: CHB patients treated with TDF monotherapy... -
- CITED
-
- Close
- SHARE
-
- Close
- Genotypic resistance to entecavir in chronic hepatitis B patients
-
Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ
- KMID: 1792593
- Korean J Hepatol.
- 2010 Jun;16(2):147-157.
- doi: 10.3350/kjhep.2010.16.2.147
BACKGROUND/AIMS: The prevalence and clinical characteristics of entecavir (ETV) resistance is not well known. The aim of this study was to determine the frequency of genotypic resistance in nonresponders and... -
- CITED
-
- Close
- SHARE
-
- Close
- New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B
-
Cho YK, Song BC
- KMID: 1128352
- Korean J Gastroenterol.
- 2011 Mar;57(3):144-149.
- doi: 10.4166/kjg.2011.57.3.144
Over the past decade, advances in the antiviral therapy in patients with chronic hepatitis B have enabled the sustained suppression of hepatitis B viral replication and the prevention of progressive... -
- CITED
-
- Close
- SHARE
-
- Close
- Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
-
Park MS, Kim BK, Kim KS, Kim JK, Kim SU, Park JY, Kim DY, Baartarkhuu O, Han KH, Chon CY, Ahn SH
- KMID: 1493572
- Clin Mol Hepatol.
- 2013 Mar;19(1):29-35.
- doi: 10.3350/cmh.2013.19.1.29
BACKGROUND/AIMS: The incidence of multidrug-resistant (MDR) chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens... -
- CITED
-
- Close
- SHARE
-
- Close
- A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus
-
Lee HJ, Choi JW, Kim TN, Eun JR
- KMID: 1381468
- Korean J Hepatol.
- 2008 Sep;14(3):381-386.
- doi: 10.3350/kjhep.2008.14.3.381
Adefovir dipivoxyl (ADV) effectively suppresses hepatitis B virus (HBV) replication but exhibits nephrotoxicity with severe hypophosphatemia when administered at a high dosage. This is the first report of severe hypophosphatemic... -
- CITED
-
- Close
- SHARE
-
- Close
- HBV DNA Loss within 24 Weeks Predicts Late Viral Breakthrough in Chronic Hepatitis B
-
Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS
- KMID: 1792811
- Korean J Gastroenterol.
- 2011 Jul;58(1):25-30.
- doi: 10.4166/kjg.2011.58.1.25
BACKGROUND/AIMS: Sustained HBV DNA reduction is necessary for biochemical remission, histological improvement, and prevention of complications. We analyzed the time taken from HBV DNA loss to viral breakthrough after antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
-
Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH
- KMID: 2373148
- Clin Mol Hepatol.
- 2016 Dec;22(4):443-449.
- doi: 10.3350/cmh.2016.0037
BACKGROUND/AIMS: It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy... -
- CITED
-
- Close
- SHARE
-
- Close
